Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.

Pharmaceutical Research
Muhammad Sadeqi NezhadAlexander Marcus Seifalian

Abstract

Chimeric antigen receptor T (CAR-T) cell therapy has been increasingly conducted for cancer patients in clinical settings. Progress in this therapeutic approach is hampered by the lack of a solid manufacturing process, T lymphocytes, and tumor-specific antigens. T cell source used in CAR-T cell therapy is derived predominantly from the patient's own T lymphocytes, which makes this approach impracticable to patients with progressive diseases and T leukemia. The generation of autologous CAR-T cells is time-consuming due to the lack of readily available T lymphocytes and is not applicable for third-party patients. Pluripotent stem cells, such as human induced pluripotent stem cells (hiPSCs), can provide an unlimited T cell source for CAR-T cell development with the potential of generating off-the-shelf T cell products. T-iPSCs (iPSC-derived T cells) are phenotypically defined, expandable, and as functional as physiological T cells. The combination of iPSC and CAR technologies provides an exciting opportunity to oncology and greatly facilitates cell-based therapy for cancer patients. However, T-iPSCs, in combination with CARs, are at the early stage of development and need further pre-clinical and clinical studies. This review will...Continue Reading

References

Jun 1, 1985·The Journal of Clinical Investigation·A CampbellM Long
Dec 18, 2001·Nature Immunology·Janice M KellyMark J Smyth
Oct 21, 2004·Blood·Ross N La Motte-MohsJuan Carlos Zúñiga-Pflücker
Apr 30, 2005·The Journal of Biological Chemistry·David J RoddaPaul Robson
Mar 23, 2006·Annual Review of Immunology·Markus G RudolphIan A Wilson
Sep 2, 2006·Science·Richard A MorganSteven A Rosenberg
Nov 22, 2007·Science·Junying YuJames A Thomson
Nov 29, 2007·Journal of Clinical Pathology·E Matutes
Mar 29, 2008·Cell Stem Cell·Robert BlellochMiguel Ramalho-Santos
Sep 27, 2008·Science·Matthias StadtfeldKonrad Hochedlinger
Apr 29, 2009·Cell Stem Cell·Hongyan ZhouSheng Ding
Jun 25, 2009·Stem Cell Reviews and Reports·Wouter Scheper, Sjef Copray
Mar 3, 2010·In Vitro Cellular & Developmental Biology. Animal·Jeremy Micah CrookGlyn Stacey
Apr 7, 2010·Stem Cell Research·Yuehong WuPeter J Hornsby
Jun 5, 2010·Molecular Biotechnology·Aaron M ElliottAnja Kammesheidt
Jul 14, 2010·Cell Stem Cell·Yuin-Han LohGeorge Q Daley
Jul 14, 2010·Cell Stem Cell·Judith StaerkRudolf Jaenisch
Dec 16, 2010·Stem Cell Research & Therapy·Guilai Shi, Ying Jin
Mar 11, 2011·Nature Reviews. Cancer·Uri Ben-David, Nissim Benvenisty
Apr 12, 2011·Nature Biotechnology·Seth M TaapkenKaren D Montgomery
Apr 19, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Steven A RosenbergMark E Dudley
May 31, 2011·Cell Stem Cell·Norikatsu MiyoshiMasaki Mori
Aug 9, 2011·Proceedings of the National Academy of Sciences of the United States of America·Hiroshi BanShin-Ichi Nishikawa
Sep 20, 2011·Nature Medicine·Luca GattinoniNicholas P Restifo
Mar 20, 2012·Stem Cell Reviews and Reports·Upinder SinghUma Lakshmipathy
Sep 12, 2012·Nature Biotechnology·Justine J CunninghamLeendert H J Looijenga

❮ Previous
Next ❯

Citations

Jul 10, 2021·Biotechnology and Bioengineering·Muhammad Sadeqi NezhadNader Bagheri
Sep 27, 2021·Molecular Therapy : the Journal of the American Society of Gene Therapy·Geoffrey L Rogers, Paula M Cannon

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.